New eczema pill shows promise in large Real-World trial
NCT ID NCT07276620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test the drug ivarmacitinib in 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis (eczema). Participants take a daily pill for up to 52 weeks, with the option to adjust the dose. Researchers will measure how well the drug clears skin rashes and reduces itching, and track any side effects. The goal is to see how well the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ivarmacitinib (a JAK inhibitor taken as a tablet)
- What this could lead to
- If successful, this could confirm ivarmacitinib as a safe and effective long-term treatment option for moderate-to-severe atopic dermatitis, helping more people manage their symptoms.
- What could go wrong
- This is a real-world study, not a blinded placebo trial, so results may be less definitive. Side effects of JAK inhibitors include infection risk and blood abnormalities, and the study is still recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged between 12 and 75 years; * Diagnosed with moderate-to-severe atopic dermatitis (AD) ; * Participants (and legal representatives for adolescents) able to understand and communicate with the investigator. Exclusion Criteria: * Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: 1. Absolute lymphocyte count of \<0.50 x 10\^9 /L (\<500/mm3); 2. Absolute Neutrophil Count (ANC) of \<1 X 10\^9/L (\<1000/mm3); 3. Hemoglobin level \< 80 g/L. * Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ. * Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability. * Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy. * Subjects with active tuberculosis or known active hepatitis B and/or hepatitis C infection. * Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems. * Female subject who is pregnant, breastfeeding, or considering pregnancy during the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.